- Home
- XERS vs CHI Comparison
XERS vs CHI Comparison
Compare XERS & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | CHI |
|---|---|---|
| Founded | 2005 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 930.8M |
| IPO Year | 2021 | 2002 |
Fundamental Metrics
Financial Performance| Metric | XERS | CHI |
|---|---|---|
| Price | $6.16 | $12.12 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $10.83 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 203.6K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.90% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.26 | $10.00 |
| 52 Week High | $10.08 | $12.15 |
Technical Indicators
Market Signals| Indicator | XERS | CHI |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 67.30 |
| Support Level | $5.79 | $10.91 |
| Resistance Level | $6.41 | $12.13 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 57.74 | 95.69 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.